aurabiosciences.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $225.08MM
Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/22/2021 | Series E | $80.48MM | $xx.xx | $283.03MM | Matrix Capital Management, Surveyor Capital, Rock Springs Capital, Adage Capital Management LP, Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital, Columbus Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
102,671,041
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Matrix Capital Management, Surveyor Capital, Rock Springs Capital, Adage Capital Management LP, Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital, Columbus Venture Partners
|
||||||
07/09/2020 | Series D-2 | $17MM | $xx.xx | $157.27MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,598,481
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Undisclosed Investors
|
||||||
04/02/2019 | Series D-1 | $40MM | $xx.xx | $139.53MM | Medicxi, Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
57,878,742
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Medicxi, Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Ysios Capital
|
||||||
12/21/2017 | Series C-2 | $12.12MM | $xx.xx | $73.09MM | Lundbeckfonden Ventures, Arix Biosciences, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR Biosciences | |
Price per Share
$xx.xx
Shares Outstanding
33,218,192
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Lundbeckfonden Ventures, Arix Biosciences, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR Biosciences
|
||||||
12/21/2017 | Series C-1 | $30.29MM | $xx.xx | $73.09MM | Lundbeckfonden Ventures, Arix Biosciences, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR Biosciences | |
Price per Share
$xx.xx
Shares Outstanding
58,109,711
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Lundbeckfonden Ventures, Arix Biosciences, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR Biosciences
|
||||||
03/05/2015 | Series B | $28.21MM | $xx.xx | $50.26MM | Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, LI-COR Biosciences | |
Price per Share
$xx.xx
Shares Outstanding
22,705,646
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, LI-COR Biosciences
|
||||||
08/17/2014 | Series A-2 | $5.37MM | $xx.xx | $22.08MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,325,021
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
07/04/2013 | Series A-1 | $8.2MM | $xx.xx | $29.11MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,298,732
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
08/26/2011 | Series A | $3.4MM | $xx.xx | $16MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,701,141
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|